Camurus AB
The answer first
Does Camurus beat the market?
Yes, Camurus has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 74% of Nordic stocks
- Quality94
- Value6
- Trend88
No. 31 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Camurus keeps must grow about 19% a year for 10 years.
Max for seven days
Follow Camurus with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Camurus
Your first answer is free, no account needed.
Do you own Camurus, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Camurus and a few more. Free, no card.
Super Stock+44.6%In short
- Camurus has risen 19.1% over the past year, including dividends.
- Overall, Camurus ranks better than 74% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 40.4%. The price is 1.7% below its peak now.
Who owns Camurus? See the major shareholders and their stakes
What do analysts think of Camurus?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 74% of Nordic stocks.
No. 31 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 21 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.04
- Asset turnoverSales divided by everything the company owns0.43
- Return on equityProfit divided by equity+15.2%
- Cash conversionOperating cash flow divided by profit1.29
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 155 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity8.7
- P/SPrice divided by sales17.8
- P/EPrice divided by earnings57.0
- P/CFPrice divided by operating cash flow44.1
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 30 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+17.3%
- 6 months+36.0%
- 9 months+42.2%
- 12 months+19.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Camurus
54 funds we follow own Camurus. The share is how much of the fund the stock makes up.
- Norway3
- Sweden51
- 3 ETFs
- PLUS Hälsovård Sverige IndexSweden · PLUS5.2%
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo4.0%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest3.8%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest3.8%
- FE Småbolag Sverige ASweden · FE Småbolag2.6%
- Öhman Sweden Micro Cap ASweden · Öhman2.4%
- Öhman Småbolagsfond ASweden · Öhman2.3%
- Kvartil Nordiska Småbolag+ Faktor ASweden · Kvartil2.0%
Show all 54
- PriorNilsson Evolve ASweden · PriorNilsson1.9%
- Aktiespararna Småbolag EdgeSweden · Aktiespararna1.7%
- Länsförsäkringar Småbolag Sverige ASweden · Länsförsäkringar1.7%
- Didner & Gerge AktiefondSweden · Didner1.4%
- Enter Select ASweden · Enter1.3%
- Pareto Sverige DSweden · Pareto1.3%
- Cicero Sverige ASweden · Cicero1.1%
- AMF Aktiefond SmåbolagSweden · AMF1.1%
- PLUS Småbolag Sverige IndexSweden · PLUS1.0%
- Xact Svenska Småbolag (UCITS ETF)Sweden · XACT · ETF0.9%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.9%
- Handelsbanken Europa Småbolag (A1 NOK)Sweden · Handelsbanken0.8%
- Handelsbanken Europa Småbolag A10 NOKSweden · Handelsbanken0.8%
- Lysa Sverige Aktier BSweden · Lysa0.8%
- Handelsbanken Hälsovård Tema (A1 SEK)Sweden · Handelsbanken0.7%
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken0.5%
- Swedbank Robur Access Edge Sweden ASweden · Swedbank Robur0.4%
- Avanza Sweden All Cap ASweden · Avanza0.4%
- Cicero World 0-50Sweden · Cicero0.4%
- Cicero Yield BSweden · Cicero0.4%
- Cicero Offensiv Hållbar ASweden · Cicero0.3%
- XACT Sverige (UCITS ETF)Sweden · XACT · ETF0.3%
- Skandia Sverige ExponeringSweden · Skandia0.3%
- SPP Aktiefond Sverige ASweden · SPP0.3%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.3%
- Nordea Inst Aktie SverigeSweden · Nordea0.3%
- Nordnet Indexfond SverigeSweden · Nordnet0.3%
- Öhman Etisk Index Sverige ASweden · Öhman0.3%
- PLUS Allabolag Sverige IndexSweden · PLUS0.3%
- Öhman Sverige Marknad Hållbar ASweden · Öhman0.3%
- AMF Aktiefond SverigeSweden · AMF0.2%
- Swedbank Robur Access Sverige ASweden · Swedbank Robur0.2%
- Skandia Världen SverigeSweden · Skandia0.2%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg0.1%
- DNB Norden Indeks ANorway · DNB0.1%
- Levler MSCI Nordic by Xtrackers UCITS ETFSweden · Levler · ETF0.1%
- KLP AksjeNorden IndeksNorway · KLP0.1%
- AMF Aktiefond VärldenSweden · AMF0.1%
- GodFond Sverige & VärldenSweden · GodFond0.1%
- Nordea Donationsmedelsfond utdSweden · Nordea0.1%
- Skandia SMART FörsiktigSweden · Skandia0.1%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
- Länsförsäkringar Sparmål 2025Sweden · Länsförsäkringar0.0%
- Länsförsäkringar Sparmål 2030Sweden · Länsförsäkringar0.0%
- Nordea Avtalspensionsfond MidiSweden · Nordea0.0%
From the funds' latest known holdings.
About Camurus
Camurus AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 320 employees.
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hype…


See the full analysis of Camurus.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card